Novel targets for immune-checkpoint inhibition in cancer
Cancer Treatment Reviews · 2023-11 · 120 · 102614
DOI: 10.1016/j.ctrv.2023.102614 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2023-11. Verfasst von Maxime Borgeaud und 6 weiteren Autor:innen. Beteiligte Einrichtung: Geneva University Hospitals, Switzerland. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 149-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Geneva University Hospitals, Switzerland.
- Centre Hospitalier Universitaire Vaudois, Switzerland.
- Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
- Geneva University Hospitals, Switzerland; Clinique Générale Beaulieu, Geneva, Switzerland. Electronic address: afriedlaender@beaulieu.ch.
Zitieren
APA
Borgeaud, M., Sandoval, J., Obeid, M., Banna, G., Michielin, O., Addeo, A., & Friedlaender, A. (2023). Novel targets for immune-checkpoint inhibition in cancer. Cancer Treatment Reviews, 120, 102614. https://doi.org/10.1016/j.ctrv.2023.102614
Vancouver
Borgeaud M, Sandoval J, Obeid M, Banna G, Michielin O, Addeo A, et al. Novel targets for immune-checkpoint inhibition in cancer. Cancer Treatment Reviews. 2023;120:102614. doi:10.1016/j.ctrv.2023.102614
BibTeX
@article{Borgeaud2023,
author = {Borgeaud, Maxime and Sandoval, Jose and Obeid, Michel and Banna, Giuseppe and Michielin, Olivier and Addeo, Alfredo and Friedlaender, Alex},
title = {Novel targets for immune-checkpoint inhibition in cancer},
journal = {Cancer Treatment Reviews},
year = {2023},
volume = {120},
pages = {102614},
doi = {10.1016/j.ctrv.2023.102614}
}
EUVIMED